LKFT
Lakefront Biotherapeutics NVMarquee-fund ownership over time
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Greenlight Capital | Q1 2022 | 18Q | $0.00 | $27 | — |
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $25 | $27 | +8% |
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $24 | $27 | +10% |
| D.E. Shaw re-entered | Q3 2024(8Q snapshot) | 7Q | $24 | $27 | +10% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $24 | $27 | +10% |
| Two Sigma Investments | Q2 2025(8Q snapshot) | 4Q | $27 | $27 | -1% |
| Point72 Asset Management | Q3 2025(8Q snapshot) | 3Q | $32 | $27 | -16% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Fundamentals
XBRL · Lakefront Biotherapeutics NVNot enough XBRL history to plot. Lakefront Biotherapeutics NVhasn't tagged revenue, net income, EPS, or operating cash flow in the SEC us-gaap taxonomy with at least two fiscal-year periods — typical for SPACs / trust vehicles, pre-revenue biotechs, recent IPOs, and foreign filers reporting under IFRS.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Lakefront Biotherapeutics NV — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 6-KFORM 6-KJun 9, 2026
- 6-KFORM 6-KJun 9, 2026
- 6-KFORM 6-KJun 5, 2026
- 6-KFORM 6-KMay 27, 2026
- 6-KFORM 6-KMay 6, 2026
- 6-KFORM 6-KApr 29, 2026
- 6-KInterim disclosure (foreign)Mar 31, 2026
- 6-KInterim disclosure (foreign)Mar 30, 2026
- 20-FAnnual report (foreign)Mar 26, 2026
- 6-KFORM 6-KMar 24, 2026
- 6-KFORM 6-KMar 17, 2026
- 6-KFORM 6-KMar 10, 2026
- 6-KFORM 6-KMar 6, 2026
- 6-KFORM 6-KMar 5, 2026
- 6-KFORM 6-KMar 4, 2026
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q3 2025 | open | $32 | $27 | -16% |
| Point72 Asset Management | Q3 2025 | open | $32 | $27 | -16% |
| Two Sigma Investments | Q2 2025 | open | $27 | $27 | -1% |
| D.E. Shaw | Q2 2025 | open | $27 | $27 | -1% |
| Citadel Advisors | Q3 2024 | Q2 2025 | $24 | $27 | +11% |
| D.E. Shaw | Q3 2024 | Q4 2024 | $24 | $28 | +15% |
| Millennium Management | Q3 2024 | open | $24 | $27 | +10% |
| Renaissance Technologies | Q3 2024 | open | $25 | $27 | +8% |
| Greenlight Capital | Q1 2022 | open | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.